| ABSTRACT Objective:To systematically evaluate the effectiveness and safety of Tanshinone ⅡA sulfonate injection in treating patients with acute cerebral infarction (ACI). Methods: Randomized controlled trials regarding ACI treated by Tanshinone ⅡA were searched in the China National Knowledge Infrastructure Database, China Science and Technology Journal Database, Wanfang Database, Chinese Biomedical Literature Database, PubMed and Cochrane Library up to October, 2016. Two reviewers independently retrieved RCTs and extracted information. The Cochrane risk of bias method was used to assess the quality of included studies, and Meta analysis was conducted with Stata 13.1 software.Results:13 studies involving 1 273 participants were included. In the Meta analysis, Tanshinone ⅡA injection combined with western medicine was significantly superior to the routine western medicine group in the total effective rates (RR=1.22, 95%CI:1.16-1.28, P<0.01), the neurologic impairment (MD=-5.08, 95%CI:-7.40-2.77, P<0.01), There was no obvious difference in reducing the worsening situation. Additionally, DH also can reduce inflammatory indexes. There were 7 studies without obvious adverse reactions. 2 studies reported 11 ADRs.Conclusion:Comparing with routine western medicine, Tanshinone ⅡA sulfonate injection combined with routine western medicine is more effective in improving the total effective rates and the neurologic impairment. But based on the limitations of the study, more high quality trials with longer following up are necessary for further evidence. |
